L
Lysiane Marthey
Researcher at University of Paris-Sud
Publications - 45
Citations - 2950
Lysiane Marthey is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: FOLFIRINOX & Prospective cohort study. The author has an hindex of 17, co-authored 43 publications receiving 2137 citations.
Papers
More filters
Journal ArticleDOI
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker,Berend R. Beumer,Eran Sadot,Lysiane Marthey,Jason E. Faris,Eric A. Mellon,Bassel F. El-Rayes,Andrea Wang-Gillam,Jill Lacy,Peter J. Hosein,Sing Yu Moorcraft,Thierry Conroy,Florian Hohla,Peter J. Allen,Julien Taieb,Theodore S. Hong,Ravi Shridhar,Ian Chau,Casper H.J. van Eijck,Bas Groot Koerkamp +19 more
TL;DR: Patients with locally advanced pancreatic cancer treated with FOLFIRINOX had a median overall survival of 24·2 months-longer than that reported with gemcitabine (6-13 months).
Journal ArticleDOI
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Valérie Vilgrain,Valérie Vilgrain,Helena Pereira,Eric Assenat,Boris Guiu,Alina Diana Ilonca,Georges-Philippe Pageaux,Annie Sibert,Mohamed Bouattour,Rachida Lebtahi,Wassim Allaham,Hélène Barraud,Valérie Laurent,Elodie Mathias,Jean-Pierre Bronowicki,Jean-Pierre Tasu,Rémy Perdrisot,Christine Silvain,René Gerolami,Olivier Mundler,Jean-François Seitz,Vincent Vidal,Christophe Aubé,Frédéric Oberti,Olivier Couturier,Isabelle Brenot-Rossi,Jean-Luc Raoul,Anthony Sarran,Charlotte Costentin,Emmanuel Itti,Alain Luciani,Alain Luciani,René Adam,Maïté Lewin,Didier Samuel,Maxime Ronot,Maxime Ronot,Aurelia Dinut,Laurent Castera,Laurent Castera,Gilles Chatellier,Gilles Chatellier,Elisabeth Delhom Christol,Alina D. Ilonca,Julie Lonjon,Mohamed Abdel-Rehim,Arnaud Dieudonné,Christophe Bazin,Carine Chagneau-Derrode,Patrick Borentain,Antoine Bouvier,Laurent Vervueren,Julia Chalaye,Hicham Kobeiter,Julien Edeline,Etienne Garin,Yan Rolland,Isabelle Archambeaud,T. Eugène,Eric Frampas,Christophe Cassinotto,Martine Guyot,Jean-Baptiste Hiriart,Bruno Lapuyade,Julien Vergniol,Philippe Bachellier,Julien Detour,Bernard Duclos,Michel Greget,Francois Habersetzer,Alessio Imperiale,Philippe Merle,Agnès Rode,Julie Morvan,Eric Nguyen-Khac,Thierry Yzet,G. Baudin,Patrick Chevallier,Abakar Mahamat,Thierry Piche,Micheline Razzouk,Patrick Hillon,Romaric Loffroy,Michel Toubeau,Julie Vincent,Gabriele Barabino,Nadia Bouarioua,Muriel Cuilleron,Marie Ecochard,Nathalie Prevot-Bitot,Vincent Leroy,J. Roux,Christian Sengel,Valérie Bourcier,Nathalie Ganne-Carrié,Olivier Seror,Sylvie Costo,Thong Dao,Jean-Pierre Pelage,Jérôme Dumortier,Francesco Giammarile,Pierre-Jean Valette,Nadia Ghazzar,Olivier Pellerin,Julien Taieb,Pierre Weinmann,Alexandra Heurgue-Berlot,Claude Marcus,Daniele Sommacale,Maria-Angéla Castilla-Lièvre,Sophie Maitre,Lysiane Marthey +111 more
TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.
Journal ArticleDOI
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
Lysiane Marthey,Christine Mateus,Cristina Mussini,Maria Nachury,Stéphane Nancey,Florent Grange,Camille Zallot,Laurent Peyrin-Biroulet,Jean-François Rahier,M. Bourdier de Beauregard,Laurent Mortier,Clélia Coutzac,Emilie Soularue,Emilie Lanoy,N. Kapel,David Planchard,Nathalie Chaput,Caroline Robert,Franck Carbonnel +18 more
TL;DR: Ipilimumab and tremelimumab may induce a severe and extensive form of inflammatory bowel disease and patients treated with anti-CTLA-4 should be advised to avoid NSAIDs.
Journal ArticleDOI
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Emilie Soularue,Patricia Lepage,Jean-Frederic Colombel,Clélia Coutzac,David Faleck,Lysiane Marthey,Michael Collins,Nathalie Chaput,Nathalie Chaput,Caroline Robert,Franck Carbonnel +10 more
TL;DR: Findings open new perspectives for possible manipulation of the gut microbiota in order to better identify responders to immune checkpoint inhibitors and to increase their efficacy and safety.
Journal ArticleDOI
Olmesartan-associated enteropathy: results of a national survey
Lysiane Marthey,Guillaume Cadiot,Philippe Seksik,Philippe Pouderoux,J. Lacroute,F. Skinazi,B. Mesnard,J. A. Chayvialle,Guillaume Savoye,Anne Druez,D. Parlier,Vered Abitbol,M. Gompel,M. Eoche,E. Poncin,R. Bobichon,P. Colardelle,Pauline Wils,H. Salloum,S. Peschard,F. Zerbib,Bertrand Meresse,Nadine Cerf-Bensussan,Georgia Malamut,Franck Carbonnel +24 more
TL;DR: A phase 3 trial and a cohort study found no association between gastrointestinal events and olmesartan, and the association has been questioned.